MAELS 2014- 3rd Annual Media, Advertising and Entertainment Legal Summit

/ By / Event, Sponsored

SpicyIP is pleased to announce the 3rd Annual Media, Advertising and Entertainment Legal Summit (MAELS 2014). Details are as follows: An aggressive industry research that Lex Witness conducted within the various stakeholders of the industry reflects a lot of ambiguity in the understanding of the current legal & regulatory regime. The 3rd Annual Edition of Media, Advertising &Entertainment Legal Summit 2014 promises to brainstorm on the challenges faced by the Media, Advertising & Entertainment Industry and we shall together look […]

MAELS 2014- 3rd Annual Media, Advertising and Entertainment Legal Summit Read More »

PLCS 2014- Pharma Legal and Compliance Summit 2014

/ By / Event, Sponsored

  SpicyIP is pleased to announce the 3rd Annual Pharma Legal & Compliance Summit 2014. The details are as follows: The Pharma Legal & Compliance Summit was launched in 2012 and ever since has successfully come up with 2 editions. We now present The 3rd Annual Edition which is to be scheduled for 19th September 2014, Mumbai. The summit brings to you a day of brainstorming sessions with the leaders and veterans of the industry. Addressing the complications and concerns

PLCS 2014- Pharma Legal and Compliance Summit 2014 Read More »

An examination of FRAND Challenges for India’s ICT Sector

/ By / Patent, Publication

SpicyIP is happy to announce that we will be starting off our very own ‘journal’ section soon! Rather than a periodical, we will (probably) be accepting and publishing entries year round. We are still finalizing details for this and will announce them in the near future – so do keep an eye out! Further, in addition to this, we have decided to publish some longer form notes sent in by our readers in a “SpicyIP Discussion Paper Series” that is being

An examination of FRAND Challenges for India’s ICT Sector Read More »

Gilead enters into licenses with 7 Indian generics for manufacture and sale of Sovaldi

/ By / Patent

Last month we reported Gilead’s slashed pricing for ‘Sovaldi’ (its anti-Hepatitis C drug) in India as well as its proposals to tie up with Indian generics for the manufacture and export of the drug (see here and here). This week has seen the concretion of these deals with 7 Indian generic companies (see here and here). The Price Slash As the earlier posts outlined in detail, Gilead has been caught in widespread controversies across the world over its pricing for sofobuvir, brand

Gilead enters into licenses with 7 Indian generics for manufacture and sale of Sovaldi Read More »

Madras HC orders reconstitution of IPAB Vice -Chairperson Selection Committee

/ By / Patent

As reported earlier this month, a miscellaneous petition seeking a stay on the appointment of a Vice- Chairperson (VC) to the Intellectual Property Appellate Board (IPAB) was filed in pursuance of Shamnad’s challenge to the constitutional validity of the Board. The matter came up today and Justice Sanjay Kishen Kaul (Chief Justice of the Madras High Court) was of the view that Justice Basha (current chairman of the IPAB) and not the Secretary, DIPP ought to be the Chairman of

Madras HC orders reconstitution of IPAB Vice -Chairperson Selection Committee Read More »

Vringo v. ZTE- ‘Expert’ Need Not Have Specialised Degree

/ By / Patent

The ongoing dispute between Vringo and ZTE has yet another update by the Delhi High Court- this time, on the scope of who is an expert under S.45 of the Indian Evidence Act. Vringo had filed a suit for infringement of Indian Patent 200,572 against ZTE. The patent was related to making handover decisions in mobile communication systems. In February this year, an ex-parte temporary injunction was granted in favour of Vringo. In August, the injunction was vacated on the

Vringo v. ZTE- ‘Expert’ Need Not Have Specialised Degree Read More »

SpicyIP Tidbit: Infrastructure and Transparency get a boost at the IP Office

/ By / Others, Patent

Mr Amitabh Kant, Secretary, Department of Industrial Policy and Promotion, Ministry of Commerce and Industry, recently inaugurated a new building that is to be used by the Intellectual Property Office. Built at a cost of nearly Rs. 30 crore, the building is said to be equipped to deal with the operations of the Patent Office as an International Searching Authority (ISA) and International Preliminary Examining Authority (IPEA) under the Patent Cooperation Treaty (PCT), Business Standard reports. A new payment gateway

SpicyIP Tidbit: Infrastructure and Transparency get a boost at the IP Office Read More »

Emcure v. Corona Remedies: Silence not acquiescence says BomHC

/ By / Trademark

In this Notice of Motion, the Bombay High Court considered the question of deceptive similarity, acquiescence and balance of convenience and decided in favour of the plaintiffs on all questions. Background: The plaintiff, EMCURE Pharmaceuticals, registered the marks OROFER and OROFER- XT in October, 1996 as word marks in Class 5 (medicinal or pharmaceutical preparations for iron deficiency, anaemia, etc.). The product in question is a film coated tablet or capsule prescribed as an iron supplement by orthopaedics and folic

Emcure v. Corona Remedies: Silence not acquiescence says BomHC Read More »

Diageo v. Khoday- An alcoholic battle for injunctions

/ By / Trademark

The Delhi High Court recently heard a trademark dispute between two alcohol companies, namely,  Diageo Brands B. V. and Khoday Breweries Ltd. Diageo Brands is well known across the world as the owner of global brands such as Johnnie Walker Black Label, Johnnie Walker Red Label, Johnnie Walker Green Label, Captain Morgan, VAT 69, Smirnoff, Guinnes and Baileys among others. Diageo contended that  Khoday had registered as well as applied for trademark registration for many marks which were confusingly and deceptively similar to

Diageo v. Khoday- An alcoholic battle for injunctions Read More »

SpicyIP Weekly Reviews (1st to 7th September & 8th to 14th September)

/ By / Others

Some very important IP developments took place early this month. Anubha blogged about the Regional Comprehensive Economic Partnership (RCEP) and how Japan is pushing for TRIPS plus commitment in the RCEP negotiation rounds. If this is accepted, it would be a great setback to India’s generic medicines industry. Thomas analysed a recent order passed by the Competition Commission of India wherein the CCI fined automobile manufacturers (including Tata Motors and Maruti Suzuki) for indulging in anti-competitive practices during sale of

SpicyIP Weekly Reviews (1st to 7th September & 8th to 14th September) Read More »

Scroll to Top